Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Why CDMO Outsourcing is Moving Earlier in Biologics Development
Learn why CDMO outsourcing is moving earlier in biologics development and how early CMC strategy can reduce late-stage risk. Read more.
9th Sep, 2026
Read
The New-Age CRDMO: Rethinking Drug Development Partnerships
Explore how the antibody drug conjugates market, AI, supply resilience and integrated CRDMOs are reshaping drug development outsourcing. Read more.
2nd Sep, 2026
Read
Flow Chemistry Approaches for Poorly Soluble Pharmaceutical Intermediates
Explore how flow chemistry supports poorly soluble pharmaceutical intermediates through better mixing, precipitation control, and crystallization. Read now.
28th Aug, 2026
Read
Advanced Strategies for Handling Unstable Intermediates with Flow Chemistry
See how flow chemistry helps control unstable intermediates, reduce scale-up risk, and improve process safety in pharma development. Explore now.
27th Aug, 2026
Read
Electrochemical cell design: Turning electron transfer into a practical synthetic tool
Explore electrochemical cell design, electron transfer, process development, and scalable pharmaceutical synthesis. Read the article.
10th Jul, 2026
Read
From Faster CLD to Smarter CMC Decisions: How Semi-Targeted Integration Changes the Biologics Game
See how semi-targeted integration can improve cell line development, reduce clone screening, and support biologics development. Read the article.
8th Jul, 2026
Read
India as a Global CRDMO Powerhouse: Debunking Quality Myths
Explore how India’s CRDMO quality systems, regulatory scrutiny, and biologics manufacturing capabilities challenge outdated quality myths. Read more.
8th Jul, 2026
Read
Oligonucleotide Analytical Development: Five Hidden Traps and How to Avoid Them
Avoid five analytical traps in oligonucleotide development, from impurity profiling to bioanalysis and validation. Read more.
8th Jul, 2026
Read
Allometric scaling vs PBPK: when each approach helps in human dose prediction
Compare allometric scaling and PBPK for human dose prediction using in vivo data and mechanistic models. Read more.
23rd Jun, 2026
Read
From PBPK modeling to first-in-human dose: how predictive DMPK can reduce early clinical risk
Explore how PBPK modeling supports human PK prediction, first-in-human dose selection, and model-informed drug development. Read more.
23rd Jun, 2026
Read